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n vitro infection model
a  b  s  t  r  a  c  t
The  aim of  this  work  was  to compare  the  pharmacological  properties  of  levoﬂoxacin  and  gati-
ﬂoxacin  against  Streptococcus  pneumoniae  by  pharmacokinetic/pharmacodynamic  (PK/PD)  modelling
of  the  time–kill  curves  employing  an  Emax model.  An in  vitro infection  model  was  used  to  sim-
ulate  free  pulmonary  ﬂuctuating  concentrations  expected  after  multiple  dosing  regimens  of  both
drugs  in humans  or constant  multiples  of the  minimum  inhibitory  concentration.  PK/PD  parameters
and  PK/PD  indices  of  the  simulated  dosing  regimens  were  compared.  The  levoﬂoxacin  EC50 (con-
centration  producing  50%  of  the  maximum  effect)  (mean  ±  standard  deviation  3.57 ± 2.16 mg/L)  was
higher  than that  for gatiﬂoxacin  (0.95  ±  0.56  mg/L)  when  simulating  multiple  dosing  regimens  as
well  as  constant  concentrations  (EC50,levoﬂoxacin =  2.75  ±  0.45  mg/L;  EC50,gatiﬂoxacin = 1.03 ± 0.52  mg/L).  The
maximum  killing  rate  constant  (kmax) was  not  statistically  different  for both  drugs  independent  of
−1 −1ﬂuctuating  (kmax,levoﬂoxacin =  0.40  ±  0.19  h ; kmax,gatiﬂoxacin =  0.48  ±  0.15  h ) or constant  concentrations
(kmax,levoﬂoxacin = 0.34  ± 0.06 h−1; kmax,gatiﬂoxacin = 0.39  ± 0.23  h−1). The  PK/PD  model  was  able  to  describe
the  effect  of  levoﬂoxacin  and  gatiﬂoxacin  against  S. pneumoniae  in  vitro  for all  the  simulations  investi-
gated.  Gatiﬂoxacin  was  more  potent  than  levoﬂoxacin,  but  both  presented  equivalent  efﬁcacy.  The  model
can  be used  for  simulating  alternative  regimens  and  optimising  therapy  to treat  streptococcal  infextions.
d th© 2011 Elsevier B.V. an
. Introduction
Although improvements in antibiotic and supportive treatment
ave occurred in recent years, community-acquired pneumonia
CAP) is an increasingly common reason for hospital admission and
till remains a major cause of both mortality and morbidity world-
ide [1]. Several factors, including extreme age and co-morbidities,
ontribute to its high mortality risk [2,3].
Despite the emergence of newly identiﬁed pathogens related to
AP, Streptococcus pneumoniae remains the most common aetiolog-
cal agent [4,5]. Respiratory ﬂuoroquinolones such as levoﬂoxacin
nd gatiﬂoxacin are effective antimicrobial agents indicated for the
reatment of lower respiratory infections, particularly CAP [6]. Lev-
ﬂoxacin and gatiﬂoxacin are also used for the treatment of chronic
ronchitis as well as urinary tract, kidney and skin infections [7,8].
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Both drugs have a broad spectrum of antimicrobial activity against
Gram-negative and Gram-positive pathogens [9].
Antimicrobial agents are evaluated based on pharmacoki-
netic/pharmacodynamic (PK/PD) indices. Using PK/PD indices,
antimicrobial activity can be classiﬁed as time-dependent, i.e.
the key factor that correlates with efﬁcacy is the percentage of
time that the antimicrobial concentration remains above the min-
imum inhibitory concentration of the pathogen (T > MIC), or as
concentration-dependent, when the ratio between antimicrobial
free peak plasma level (fCmax) and MIC  (fCmax/MIC) or between
area under the free plasma concentration–time curve (fAUC) and
MIC (fAUC/MIC) better forecast bacterial eradication [10]. Although
both fCmax/MIC and fAUC0–24h/MIC correlate with successful ther-
apeutic outcomes for ﬂuoroquinolones, studies advocate that the
fAUC0–24h/MIC ratio is the best index to predict the therapeutic out-
come of ﬂuoroquinolones [11,12]. Data from in vitro, animal and
clinical studies suggest that an fAUC0–24h/MIC ratio between 25 and
Open access under the Elsevier OA license.34 is the target for ﬂuoroquinolones to permit bacterial eradication
in CAP caused by S. pneumoniae [13]. However, other authors sug-
gest that for CAP due to this microorganism, an fAUC0–24h/MIC ratio
≥30 is predictive of infection outcome [14–19].
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Although the MIC  is a good PD parameter to describe the antibac-
erial potency of a drug, it is a threshold concentration with poor
recision, determined under static in vitro conditions. In vivo, bac-
eria are exposed to ﬂuctuating peak and trough concentrations and
he antibacterial activity is a result of a dynamic concentration- and
ime-dependent process [20]. Consequently, PK/PD indices that use
he MIC  are limited by the same boundaries. Furthermore, PK/PD
ndices deﬁne target values that ensure bacterial eradication, not
llowing for comparisons between different dosing regimens of the
ame drug, efﬁcacy comparison of different drugs used to treat the
ame infection, or outcome prediction for alternative regimens.
Aiming  to overcome these limitations, in PK/PD modelling the
D effect determined in time–kill experiments is modelled tak-
ng into consideration the pharmacokinetics of the antimicrobial
t the infection site. As a result, a mathematical description of the
ntimicrobial effect–time proﬁle is obtained and pharmacologi-
ally meaningful parameters are derived. These parameters allow
ot only to describe the antibacterial behaviour of the drug under
nvestigation but also to compare drugs of the same class for treat-
ng a speciﬁc infection as well as to simulate the effect over time of
lternative regimens.
Considering that most infections occur in peripheral tis-
ues and not in the bloodstream, and that only free drug
oncentrations exhibit a pharmacological effect, antimicrobial
ree tissue levels should be used in PK/PD modelling. In gen-
ral, ﬂuoroquinolones have extensive tissue penetration, showing
UCfree,tissue/AUCfree,plasma ratios close to 1. Levoﬂoxacin showed
atios  between 0.85 in skeletal muscle [21] and 1.1 in subcutaneous
dipose tissue [22] in humans. Free pulmonary concentrations of
evoﬂoxacin have been determined by microdialysis in healthy
ndividuals following cardiac surgery [23]. Using the data presented
n this paper, levoﬂoxacin estimated pulmonary penetration was
etermined to be 0.82. Our group previously demonstrated that
atiﬂoxacin easily penetrates into pulmonary Wistar rat tissue [24].
ree pulmonary levels of the drug could be predicted using PK
arameters derived from total plasma concentrations and were
imilar to free plasma levels. The lung penetration factor was  found
o be 1.08.
The  purpose of this study was to compare pharmacologically
he effects of levoﬂoxacin and gatiﬂoxacin against S. pneumoniae by
K/PD modelling of the time–kill curves obtained using an in vitro
xperimental infection model where the expected lung free levels
f both drugs following different dosing regimens in humans were
imulated.
. Materials and methods
.1.  Bacterial strains and growth media
Streptococcus pneumoniae ATCC 49619 was kept frozen at −70 ◦C
n sterile skim milk (Acumedia, Lancing, MI)  with a drop of ster-
le sheep blood. For the experiments, the strain was  transferred
o Mueller–Hinton agar (MHA) (Difco, Detroit, MI)  plates supple-
ented with 5% sheep blood (McBarth, Porto Alegre, Brazil) and
as incubated for 18–24 h at 35 ± 1 ◦C in a CO2 atmosphere. For
he inoculum preparation, isolated colonies were re-suspended in
terile saline to reach a turbidity equivalent to a 0.5 McFarland
tandard.
.2. Antimicrobials and susceptibility testingLevoﬂoxacin (99.7%) and gatiﬂoxacin (100%) were donated by
ristalia and Bristol-Myers Squibb (São Paulo, Brazil), respectively.
ICs of levoﬂoxacin and gatiﬂoxacin were determined in tripli-
ate using the broth macrodilution method according to proceduresmicrobial Agents 38 (2011) 307– 313
outlined  by the Clinical and Laboratory Standards Institute (CLSI)
[25].
2.3. In vitro model of infection
A  simple one-compartment in vitro model was  used to study the
PD effect of ﬂuoroquinolones against S. pneumoniae following mul-
tiple intermittent dosing of the drugs or constant concentrations.
The in vitro model consisted of a 50 mL  culture ﬂask containing
20 mL of Todd–Hewitt broth (Difco, Sparks, MD). The medium was
prepared according to the manufacturer’s instructions and was
autoclaved at 121 ◦C prior to use. Withdrawal and replacement
of broth solution for the simulation of decreasing concentrations
were performed at ﬁxed time intervals using a sterile 0.22 m ﬁl-
ter, and the bacterial count was  kept unchanged in the medium. An
aliquot of the S. pneumoniae suspension [108 colony-forming units
(CFU)/mL] was added to the system to achieve a consistent starting
inoculum of ca. 5 × 105 CFU/mL.
To ensure that bacteria were in logarithmic growth phase prior
to antimicrobial exposure, experiments were previously performed
to determine the lag time. After 2 h of incubation, a time zero sam-
ple was  taken and the drug was  added to the ﬂask. Bacteria were
exposed to different initial concentrations of both ﬂuoroquinolones
corresponding to the expected free peak levels of the drugs in pul-
monary tissue. To reproduce the half-life of each drug, a stepwise
dilution procedure was  followed. At 30-min intervals, aliquots of
the experimental media containing the drugs were withdrawn and
were replaced by drug-free sterile broth solution at 35 ± 1 ◦C dur-
ing 24 h of experiment. In another set of experiments, bacteria were
exposed to different constant concentrations of both drugs and the
kill curves were built up to 12 h.
To assess bacterial density over time, samples were collected
every 2 h up to the end of the experiment and were serially diluted
10-fold in sterile normal saline. Two experiments were followed up
to 4 h collecting samples every 30 min [levoﬂoxacin 1000 mg every
24 h (q24h) and gatiﬂoxacin 200 mg  q24h]. Aliquots of each diluted
sample were plated in duplicate. All experiments were conducted
in triplicate. Together with each treatment, one control experiment
was carried out to assure bacterial growth in the in vitro model.
Following  18–24 h of incubation on MHA  plates supplemented
with 5% sheep blood, the number of CFU/mL in the samples
was determined. The lowest level of detection was 200 CFU/mL.
Time–kill curves were constructed by plotting log10 CFU/mL against
time. Logarithmic reductions in bacterial counts were determined
by subtracting 24 h CFU/mL values from the starting inoculum.
2.4. Pharmacokinetics of ﬂuoroquinolones in the in vitro infection
model
To simulate the pharmacokinetics in the in vitro infection model,
drugs were added to the experimental ﬂask aiming to reach the
free pulmonary peak concentration (fCmax) expected for each drug
regimen simulated.
Levoﬂoxacin expected free concentrations in lung were calcu-
lated based on the experiments conducted by Hutschala et al. [23]
using microdialysis in patients who received conventional 500 mg
once-daily dosing of the drug. Free lung levels of levoﬂoxacin in
this study showed elimination following two slopes, with 30 min
and 7 h half-lives, respectively. To simulate this elimination proﬁle
in vitro, in the ﬁrst step-dilution 10 mL  of media was withdrawn
and replaced by fresh broth. In the following steps, 0.97 mL of the
medium was exchanged by fresh broth.Levoﬂoxacin free levels in the in vitro infection model were
described by Eq. (1):
C  = ae−˛t + be−ˇt (1)
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Table 1
Pharmacokinetic/pharmacodynamic (PK/PD) indices associated with the simulated dosage regimens for levoﬂoxacin and gatiﬂoxacin, and PK/PD parameters determined by
modelling  the killing effect of levoﬂoxacin and gatiﬂoxacin against Streptococcus pneumoniae to an Emax model with ﬂuctuating concentrations.
Simulated dose regimen Daily dose (mg) fCmax (mg/L) fCmax/MIC fAUC0–24h (mg  h/L) fAUC0–24h/MIC (h) EC50 (mg/L) kmax (h−1) MSC  (R2)
Levoﬂoxacin (MIC = 1.0 mg/L)
250 mg  q24h 250 3.2 3.2 15 15 7.14 0.70 3.0 (0.97)
167  mg  q8h 500 2.2 2.2 30 30 4.98 0.70 3.7 (0.97)
250  mg  q12h 500 3.2 3.2 30 30 2.83 0.30 2.8 (0.90)
500  mg  q24h 500 6.4 6.4 30 30 5.71 0.37 2.3 (0.90)
375  mg  q12h 750 4.9 4.9 45 45 3.00 0.32 3.7 (0.97)
750  mg  q24h 750 9.8 9.8 45 45 2.20 0.30 5.0 (0.99)
500  mg  q12h 1000  6.4 6.4 60 60 0.87 0.17 4.6 (0.99)
1000  mg  q24h 1000 12.8 12.8 60 60 1.79 0.35 5.1 (0.99)
Mean  ± S.D. 3.57 ± 2.16* 0.40 ± 0.19
Gatiﬂoxacin (MIC = 0.5 mg/L)
50  mg  q24h 50 0.35 0.7 3.4 6.8 0.57 0.42 2.9 (0.92)
50  mg  q12h 100 0.35 0.7 6.8 13.6 0.38 0.3 3.6 (0.96)
100  mg  q24h 100 0.7 1.4 6.8 13.6 1.35 0.57 4.4 (0.98)
200  mg  q24h 200  1.4 2.8 13.6 27.2 1.50 0.64 4.3 (0.99)







































aCmax, free peak concentrations in plasma; MIC, minimum inhibitory concentration; f
0% of the maximum effect; kmax, maximum killing rate constant; MSC, model selec
* Statistical difference (  ˛ = 0.05).
here C is the expected free lung concentration in humans at any
ime t, a and b are the intercepts for the ﬁrst and second elimination
ates, respectively, and  ˛ and  ˇ are the constant rates representing
he ﬁrst and the second elimination, respectively. The values of the
ybrid constants a, b,  ˛ and  ˇ were calculated based on the free
ulmonary data reported for the 500 mg  dose [23]. Assuming linear
harmacokinetics, peak levels for the other dosing regimens were
alculated.
Gatiﬂoxacin free peak pulmonary levels in humans were
ssumed to be similar to free plasma levels, based on the drug
issue penetration experiments conducted by our group [24], and
ere determined using plasma concentrations reported by Zhang
t al. [26] corrected by a protein binding of 20% [27]. An elimination
alf-life of 7.5 h was simulated.
Gatiﬂoxacin free levels in the in vitro infection model were
escribed by Eq. (2):
 = Cmaxe−ket (2)
here  Cmax is the peak free concentration after dosing and ke is the
limination rate constant.
The  dosing regimens simulated and the corresponding free peak
oncentrations of each drug added to the in vitro model are shown
n Table 1, as well as the PK/PD indices calculated. The AUC over 24 h
AUC0–24h) for both ﬂuoroquinolones was determined by trape-
oidal rule.
For  the experiments where constant concentrations were sim-
lated, both drugs were added to the infection model at levels
orresponding to multiples of the MIC  and were kept constant
hrough the experiments (in triplicate). The same procedures
escribed for ﬂuctuating concentrations were employed to deter-
ine the CFU/mL counts every 2 h up to 12 h.
.5. Determination of antimicrobial concentrations in the in vitro
nfection  model
To  assure that the stepwise dilutions used in the in vitro
nfection model closely resemble the elimination kinetics of both
rugs expected in humans, samples of broth taken from each
reatment were assayed. A high-performance liquid chromatog-
aphy (HPLC) method was developed and validated to analyse
hese samples. The system employed a reversed-phase Shim-Pack
LC-ODS column (Chiyoda-Ku, Tokyo, Japan) and ﬂuorescence
etection (295 nm excitation wavelength and 480 nm extinction
avelength). The mobile phase consisted of 2.5 mM  phosphoric
cid:methanol:acetonitrile:triethylamine (64.8:15:20:0.2, v/v/v/v)rea under the free plasma concentration–time curve; EC50, concentration producing
iterion; q24h, every 24 h; q8h, every 8 h; q12h, every 12 h; S.D., standard deviation.
at  a ﬂow rate of 1.0 mL/min. Proteins present in broth samples were
precipitated with methanol. Samples were vortexed, centrifuged
(6800 × g, 21 ◦C, 12 min) and the supernatants were injected in the
Shimadzu® HPLC system (Chiyoda-Ku). Levoﬂoxacin was used as an
internal standard when gatiﬂoxacin was evaluated, and vice versa.
The levoﬂoxacin assay was linear (r ≥ 0.9987) over a concentra-
tion range of 0.25 mg/L to 6.0 mg/L. The intra-assay and inter-assay
precision for the 0.6, 1.5 and 4.5 mg/mL  quality control samples did
not exceed 1.08%, 1.01% and 0.48%, with 1.99%, 2.01% and 3.23%
coefﬁcient of variation (CV), respectively. The gatiﬂoxacin assay
was linear (r ≥ 0.9988) over a concentration range of 0.15 mg/L to
3.0 mg/L. The intraday and interday precision for the 0.4, 1.2 and
2.5 mg/mL  quality control samples did not exceed 2.06%, 1.35% and
4.21%, with 1.1%, 0.57% and 1.63% CV, respectively.
2.6. Pharmacodynamic data analysis
The experimental mean effect for each dosing regimen investi-
gated was ﬁtted to an Emax (sigmoidal effect/concentration model)
model using the non-linear regression software Scientist® v. 2.01










where  dN/dt is the change in the number of bacteria as a function of
time, k0 (h−1) is the bacterial growth rate constant in the absence
of antibiotic, kmax (h−1) is the maximum killing rate constant, EC50
(mg/L) is the concentration of antimicrobial necessary to produce
50% of the maximum effect, C (mg/L) is the concentration of drug
at any time (t) and N (CFU/mL) is the number of viable bacteria at
the beginning of the experiment. For the experiments simulating
ﬂuctuating levoﬂoxacin and gatiﬂoxacin free pulmonary levels, the
term C was  replaced by Eqs. (1) and (2), respectively. For the con-
stant concentration simulations, the term C was kept constant at a
level corresponding to each multiple of the MIC  investigated.
For  the control experiment, bacterial growth was ﬁtted to Equa-
tion 4 in which the variation in the number of bacteria in the
infection model (dN/dt) is a function only of the bacterial growth
rate constant (k0) and the inoculum (N):dN
dt
= k0N (4)
The  k0 was  determined by simultaneous ﬁtting of all control
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xed at 0.057 h−1 and the other parameters (EC50 and kmax) were
stimated individually for each dosing regimen investigated.
The  coefﬁcient of determination (R2) and the model selection
riterion (MSC), given by the software Scientist®, as well as the
orrelation between observed and calculated values were used as
riteria for the goodness of ﬁt. No weighting factor was used to ﬁt
he data sets to the Emax model. The PK/PD parameters determined
y modelling the killing effect of both drugs were compared by
tudent’s t-test (  ˛ = 0.05).
.  Results
The MIC  for levoﬂoxacin (1.0 mg/L) against S. pneumoniae ATCC
9619 was two-fold that determined for gatiﬂoxacin (0.5 mg/L),
n agreement with previously reported values [25]. The half-lives
etermined experimentally for levoﬂoxacin (6.9 ± 0.1 h) and gati-
oxacin (7.4 ± 0.1 h) were in agreement with the values simulated,
onﬁrming that the stepwise dilutions were adequate to mimic  the
uctuating free concentrations expected in lung.
Streptococcus pneumoniae time–kill curves after multiple dos-
ng are illustrated in Figs. 1 and 2 for levoﬂoxacin and gatiﬂoxacin,
espectively. Fig. 3 shows the time–kill curves when constant
oncentrations were simulated. All levoﬂoxacin multiple-dose reg-
mens produced bacterial killing during the initial 8 h of treatment,
ith different intensity depending on the regimen investigated. For
atiﬂoxacin, bacterial killing was observed during the initial 16 h
ollowing multiple dosing.
A 3-log reduction (99.9%) in the number of S. pneumoniae in
he medium was  observed for all treatments simulated except for
evoﬂoxacin 250 mg  every 12 h (q12) and q24h, levoﬂoxacin 500 mg
24h and gatiﬂoxacin 50 mg  q24h. For constant concentrations, a 3-
og reduction in CFU was observed for levoﬂoxacin and gatiﬂoxacin
hen concentrations similar to MIC  and 2× MIC  were evaluated.
The  PK/PD parameters obtained by modelling bactericidal
ffect to ﬂuctuating and constant concentrations are presented in
ables 1 and 2, respectively. The PK/PD indices calculated for each
osing regimen investigated for both ﬂuoroquinolones are also pre-
ented in Table 1.
It  can be observed in Figs. 1–3 that the PK/PD model adequately
escribed both ﬂuoroquinolones’ antimicrobial effect, with MSC
alues for the curve ﬁtting greater than 2.3. The kmax determined
or both drugs using different regimens was statistically similar
 ˛ = 0.05) (Tables 1 and 2). The mean ± standard deviation EC50
etermined for levoﬂoxacin (3.57 ± 2.16 mg/L) was higher than
hat determined for gatiﬂoxacin (0.95 ± 0.56 mg/L) when multiple-
osing was simulated in vitro (Table 1) as well as when constant
oncentrations were simulated (Table 2) where EC50,levoﬂoxacin was
.75 ± 0.45 mg/L and EC50,gatiﬂoxacin was 1.03 ± 0.52 mg/L. Inde-
able 2
harmacokinetic/pharmacodynamic (PK/PD) parameters determined by modelling
he killing effect of constant concentrations of multiples of the minimum inhibitory
oncentration (MIC) of levoﬂoxacin and gatiﬂoxacin against Streptococcus pneumo-
iae to an Emax model.
Drugs and dosing regimens EC50 (mg/L) kmax (h−1) MSC (R2)
Levoﬂoxacin (MIC = 1.0 mg/L)
0.5× MIC  2.49 0.29 4.4 (0.99)
1× MIC  3.27 0.33 4.4 (0.99)
2× MIC  2.50 0.40 4.4 (0.99)
Average ± S.D. 2.75 ± 0.45* 0.34 ± 0.06
Gatiﬂoxacin (MIC = 0.5 mg/L)
0.5×  MIC  0.64 0.16 5.6 (0.98)
1× MIC  0.83 0.38 5.6 (0.99)
2× MIC  1.62 0.62 5.6 (0.99)
Average ± S.D. 1.03 ± 0.52* 0.39 ± 0.23
C50, concentration producing 50% of the maximum effect; kmax, maximum killing
ate  constant; MSC, model selection criterion; S.D, standard deviation.
* Statistical difference (  ˛ = 0.05).microbial Agents 38 (2011) 307– 313
pendent of the regimen investigated (constant or ﬂuctuating
concentration), the EC50 of each ﬂuoroquinolone was statistically
similar (  ˛ = 0.05).
4. Discussion
PK/PD modelling of the more realistic time–kill curves has the
advantage of describing the PD effect by parameters such as EC50,
which describes the potency of the drug, and kmax, which repre-
sents drug efﬁcacy, allowing for comparison of drugs used to treat
a particular infection under similar experimental conditions.
The  results obtained by ﬁtting the experimental data to the Emax
model showed that the model was  adequate to describe the curves
of antimicrobial effect for both drugs independently of the dos-
ing regimen investigated (Figs. 1–3). The pharmacological effects
of other ﬂuoroquinolones such as ciproﬂoxacin [28,29] and nor-
ﬂoxacin [30] were already evaluated by similar Emax models.
Comparison of the PK/PD average parameters obtained from the
time–kill curve ﬁtting showed that both drugs were equally efﬁ-
cacious but that gatiﬂoxacin was more potent than levoﬂoxacin
to treat S. pneumoniae infection when multiple-dose regimens or
constant multiples of the MIC  were simulated (Tables 1 and 2).
The PD effect of these quinolones can be viewed from a different
perspective. When contrasting both drugs’ dosing regimens with
equivalent fCmax/MIC indices one can reach a different conclusion.
Comparing, for instance, the regimens that produced fCmax/MIC
close to 3 times the MIC  for levoﬂoxacin (250 mg q12h) and
gatiﬂoxacin (200 mg  q24h) one can observe that the effect of
gatiﬂoxacin was more pronounced, showing bigger kmax values
(Table 1; Figs. 1 and 2). Similar behaviour can be observed when
constant multiples of the MIC  were used. Comparing the time–kill
curves for the equipotent concentration of 2× MIC  (Fig. 3), for exam-
ple, the number of CFU decreased faster for gatiﬂoxacin than for
levoﬂoxacin, resulting in a bigger kmax (Table 2). The same can be
observed for the other concentrations investigated. According to
this observation, gatiﬂoxacin appears to be more potent and efﬁ-
cacious than levoﬂoxacin in eradicating infection produced by this
bacterial strain.
Use  of PK/PD indices to select the best dosing schedule for
antimicrobial therapy is still one of the main approaches in clin-
ical practice. When levoﬂoxacin was  ﬁrst approved by the US Food
and Drug Administration (FDA), the dosing regimen recommended
was 500 mg  q24h. Assuming that the fAUC0–24h/MIC index is the
best predictor of the drug effect, fractionating the total daily dose
should not interfere with the ﬁnal effect. In the same manner,
if the fCmax/MIC was the best index, 500 mg once-daily would
be more effective. The results observed in Fig. 1 for levoﬂoxacin
167 mg  every 8 h (Fig. 1A), 250 mg  q12h (Fig. B) and 500 mg  q24h
(Fig. 1D) showed that reducing the dosing interval had a signiﬁcant
impact on levoﬂoxacin bactericidal activity, with the more frequent
administration (three times daily) being the more effective treat-
ment simulated for a daily dose of 500 mg.  These data could not
be predicted or explained by any one of the three PK/PD indices
because the fAUC0–24h/MIC was  the same for all treatments (30 h),
the fCmax/MIC was bigger and the T > MIC  was longer for the sin-
gle daily dose, which was shown to be the least effective of the
three dosing regimens simulated. The explanation for this effect is
unclear so far.
These  results indicate that it does make a difference if a total
daily dose is given once, twice or three times a day, although the
fAUC/MIC is the same. The same observation was  made by Sánchez
Navarro et al. [31], for instance, after comparing ciproﬂoxacin stan-
dard dosage regimens (250 mg/12 h versus 500 mg/24 h) for the
treatment of urinary tract infections. Since the fAUC0–24h was  the
same for the same daily dose, both regimens should present simi-
lar bactericidal effect. However, the 500 mg/24 h dosing regimen
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rig. 1. Levoﬂoxacin ﬁtted time–kill curves following (A) 167 mg  every 8 h, (B) 250
F) 750 mg  q24h, (G) 500 mg  q12h and (H) 1000 mg q24h. , Control without drug;
olony-forming units.
roduced a more favourable antimicrobial proﬁle in their study
31].When increasing the single daily dose of levoﬂoxacin from
00 mg  to 750 mg  or to 1000 mg  the drug was found to be more
ffective against S. pneumoniae owing to higher exposures that
esulted in fAUC0–24h/MIC ratios of 45 and 60, respectively. Theseery 12 h (q12h), (C) 250 mg every 24 h (q24h), (D) 500 mg  q24h, (E) 375 mg q12h,
ated group. n = 3 experiments/group. Errors bars indicate standard deviation. CFU,
results  agree with those reported by Lister [17] who  suggested that
when the levoﬂoxacin fAUC0–24h/MIC ratio falls below 30, the like-
lihood of bacterial eradication is diminished. Fractionating these
higher total daily doses resulted in less effective treatments as can
be seen in the time–kill curves after 375 mg  q12h (Fig. 1E) or 500 mg
q12h (Fig. 1G) as well as in the values of kmax reported in Table 1,
312 L. Tasso et al. / International Journal of Antimicrobial Agents 38 (2011) 307– 313













dig. 2. Gatiﬂoxacin ﬁtted time–kill curves following (A) 50 mg  every 24 h (q24h), (
reated group. n = 3 experiments/group. Errors bars indicate standard deviation. CFU
lthough a reduction of >3 log CFU was observed for these regi-
ens in the time interval evaluated. In this case it seems that the
Cmax/MIC index was a better predictor of infection outcome rather
han fAUC0–24h/MIC. These ﬁndings corroborate those obtained by
oreddin et al. [32], which concluded that a daily dose of 750 mg
f levoﬂoxacin leads to a higher probability of PD target attain-
ent and improved bacteriological outcome against S. pneumoniae
n patients with CAP, in addition to decreasing the length of therapy.
Gatiﬂoxacin recommended clinical dosing regimens were a
00 mg  or 400 mg  daily dose. The dose range evaluated in this study
ig. 3. Levoﬂoxacin (A) and gatiﬂoxacin (B) time–kill curves for constant concentrations 
 mg/L for levoﬂoxacin and 0.5 mg/L for gatiﬂoxacin. , Control without drug; , 0.5× MI
eviation.  CFU, colony-forming units.mg every 12 h, (C) 100 mg  q24h and (D) 200 mg  q24h. , Control without drug; ,
ny-forming units.
was 50–400 mg/day. For the 400 mg  daily dose, the killing effect
was so pronounced that it was  not possible to count bacteria in the
model after 2 h of experiment (data not shown). The 50 mg q12h,
100 mg  q24h and 200 mg  q24h dosing regimens simulated in vitro
produced >3 log reduction in CFU in 24 h (Fig. 2).
Gatiﬂoxacin 50 mg  q12h and 50 mg  q24h, which are dosing reg-
imens with a peak concentration of 0.35 mg/L, lower than the drug
MIC  for S. pneumoniae, produced CFU reduction for a period longer
than 12 h (Fig. 2). This suggests that gatiﬂoxacin subinhibitory con-
centrations produce a bactericidal effect and conﬁrm that the MIC
of multiples of the respective minimum inhibitory concentration (MIC). MICs were
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s a threshold value that has to be viewed with care. For all regimens
nvestigated except 200 mg  q24h, bacteria re-growth was observed
y the end of the experimental period. The effective 200 mg  q24h
nd 400 mg  q24h were the only gatiﬂoxacin regimens with an
AUC0–24h/MIC ratio close to or greater than 30. In this context,
hese results support the recommended dose of gatiﬂoxacin 200 mg
r 400 mg  q24h as regimens effective for S. pneumoniae eradica-
ion and suggest that the fAUC0–24h/MIC ratio is a good predictor of
nfection outcome for this ﬂuoroquinolone.
In the experiments where constant multiples of the MIC  were
imulated, the time–kill curves for both ﬂuoroquinolones showed
 large difference in the CFU count after 12 h when comparing
he effect of concentrations representing 0.5× MIC  and 1× MIC
Fig. 3). Whilst a concentration equivalent to 0.5× MIC  only slowed
own bacterial growth, concentrations similar to the MIC  or 2×
IC  actually resulted in killing, with the higher concentrations pro-
ucing bacterial eradication after 6 h or 8 h for gatiﬂoxacin and
evoﬂoxacin, respectively. Although gatiﬂoxacin was  apparently
ore efﬁcacious and potent when comparing both drugs for the
ame MIC  multiple, neither the EC50 nor the kmax averages were sta-
istically different (  ˛ = 0.05). Comparison of these parameters with
hose obtained for each drug after ﬂuctuating concentrations were
ot statistically different either. These results indicate that if these
uoroquinolones were used as constant-rate infusion, concentra-
ions equivalent to twice the bacterial MIC  would be effective.
The  results obtained using the in vitro model to build the
ime–kill curves and subsequently modelling with an Emax PK/PD
odel agreed with the results reported from clinical studies and
llowed for a better comparison of dosing regimens for these ﬂuo-
oquinolones. The results also indicate that the target values of the
K/PD indices fCmax/MIC and fAUC0–24h/MIC cannot be universally
pplied to predict bacterial eradication for either one of the drugs
nvestigated besides their inability to serve as a guide to compare
rugs in the same antimicrobial class.
. Conclusions
The PK/PD Emax model employed adequately described lev-
ﬂoxacin and gatiﬂoxacin time–kill curves when ﬂuctuating or
onstant concentration were simulated against S. pneumoniae in an
n vitro model of infection generating parameters that allowed for
omparison of the potency and efﬁcacy of these ﬂuoroquinolones
ollowing different dosing regimens. The model can be used for
imulating regimens not investigated and for optimising both drug
egimens to treat streptococcal infections.
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